Hans A Schlößer - CAP 12

Tumor-specific endogenous immune response and immune escape in gastrointestinal Cancer


Immune checkpoint inhibition (CKI) demonstrated remarkable efficacy in several kinds of cancer, representing a major breakthrough in cancer therapy. These therapies are unique, as the primary target is not the tumor cell itself, but the crosstalk between immune cells and cancer cells in the tumor microenvironment. We described a negative prognostic impact of PD-L1 expression on tumor cells in esophago-gastric adenocarcinoma (GC) and CKI is effective in metastatic disease. Interestingly, efficacy of CKI is often not limited to patients with expression of the relevant protein on tumor cells. Recent publications demonstrate that expression of PD-L1 on tumor-infiltrating lymphocytes and tumor cells are of similar importance for immune escape, which explains treatment response in patients with PD-L1 negative tumors. Despite the promising results of early studies, only a minor fraction of patients responds to CKI. Preexisting endogenous immune responses seem to be crucial for immune checkpoint inhibition. A successful immune recognition depends on a broad spectrum of immune-related tumor cell intrinsic or extrinsic aspects and can so far only be predicted partially by very few markers (e.g. mutational burden, PD-L1 expression). Hence, multidimensional analyses of tumor immunogenicity including the immune infiltrate, private and shared tumor antigens, tumor specific immune response and immune escape are crucial to further improve therapeutic efficacy and translational research for this novel aspect of cancer therapy.
We aim to decipher endogenous tumor-specific immune response with a clear focus on GI Cancer. Detailed analyses of endogenous immune response against private and shared antigens will be performed using genomic and functional analyses in preclinical models, untreated tumor samples and patients receiving immune checkpoint inhibition.

Clinical/medical relevance and sustainability in disease understanding

Our research has immediate translational relevance as endogenous immune response is probably the most relevant factor determining success or failure of emerging immunotherapies. Taken together, our analyses hopefully contribute to an implementation of immunotherapy into treatment algorithms of gastrointestinal cancer, improve translational analyses and support a tailored design of future clinical trials. This could be of similar relevance to cancers of different origins.

Dr. Hans A Schlößer

Dept. of General, Visceral and Cancer Surgery / RG location - CMMC Building

Dr. Hans Schlößer

Principal Investigator CAP 12


Work +49 221 478 89612 (Labor)

Work +49 221 478 4803 (Oberarzt-Sekretariat)

Kerpener Str. 62
50937 Köln

Publications - Hans A Schlößer

Link to PubMed

Group Members

Kerstin Wennhold (PostDoc)
Maria Garcia-Marquez
Martin Thelen
(PhD student)
Elena Staib
(MD Student)
Alexandra Kryscio
(Master student)
Rabi Raj Datta
(MD, clinical associate)
Philipp Gödel
(MD, clinical associate)
Sibylle Mellinghoff
(MD, clinical associate)
Katharina Leuchte
(MD, clinical associate)
Isabel Garcia-Marquez
Pauline Volkmar
Sabrina Reuter